You have 9 free searches left this month | to do more

Carfilzomib

Carfilzomib is a drug used to treat Multiple Myeloma, Recurrent Plasma Cell Myeloma, Lymphoma, and other conditions. Carfilzomib is being actively studied in 83 studies and prior, has been studied in 56.

Top SponsorsTop SitesTop Investigators
AmgenHackensack University Medical CenterJonathan Kaufman
M.D. Anderson Cancer CenterMayo ClinicAjai Chari
National Cancer Institute (NCI)Washington University School of MedicineAjay Nooka
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies - 2020
Completed
Has Results
  • Hematologic Malignancies
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Hospital
2021-12-03
Dec 3, 2021
C
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma - 2020
Terminated
Has Results
  • Hodgkin Disease
  • Lymphoma, Non-hodgkin
  • New York, New York
    Columbia University Irving Medical Center - Center for Lymphoid
2021-06-28
Jun 28, 2021
P
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
2021-11-25
Nov 25, 2021
L
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)
Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Maywood, Illinois
    Loyola University Medical Center
2021-04-23
Apr 23, 2021
i
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
Recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib
  • Frankfurt, Germany
    Centrum für Hämatologie und Onkologie Bethanien
2021-04-12
Apr 12, 2021
T
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
2022-01-31
Jan 31, 2022
O
Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2022-03-11
Mar 11, 2022
C
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma - 2022
Completed
Has Results
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Edmonton, Alberta, Canada
  • +8 more
2022-02-01
Feb 1, 2022
U
Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma - 2021
Completed
  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Carfilzomib
  • +2 more
  • Davis, California
  • +2 more
2021-04-21
Apr 21, 2021
U
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
Recruiting
  • Myeloma
  • Multiple Myeloma
  • Chicago, Illinois
    The University of Chicago
2021-09-15
Sep 15, 2021
M
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma - 2018
Completed
  • Contiguous Stage II Adult Lymphoblastic Lymphoma
  • +5 more
  • carfilzomib
  • +10 more
  • Sacramento, California
    University of California Davis
2022-03-08
Mar 8, 2022
B
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Melbourne, Victoria, Australia
  • +2 more
2022-03-01
Mar 1, 2022
H
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +3 more
  • Hackensack, New Jersey
    Hackensack Meridian Health - John Theurer Cancer Center
2022-04-01
Apr 1, 2022
U
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Birmingham, United Kingdom
  • +12 more
2021-10-01
Oct 1, 2021
S
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers - 2021
Completed
  • Neuroendocrine Cancer
  • Carfilzomib
  • Denver, Colorado
  • +9 more
2021-06-21
Jun 21, 2021
P
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Recruiting
  • Relapsed Solid Tumors
  • +3 more
  • Carfilzomib
  • +2 more
  • Phoenix, Arizona
  • +7 more
2021-07-06
Jul 6, 2021
O
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
Recruiting
  • Myeloma
  • Carfilzomib
  • +3 more
  • Copenhagen, Denmark
  • +3 more
2021-09-15
Sep 15, 2021
T
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients - 2021
Completed
  • Myeloma Multiple
  • +3 more
  • Carfilzomib
  • +3 more
  • Afula, Israel
  • +13 more
2022-01-26
Jan 26, 2022
O
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +5 more
  • Encinitas, California
  • +6 more
2020-08-12
Aug 12, 2020
M
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
Active, not recruiting
  • MULTIPLE MYELOMA (MM)
  • Carfilzomib
  • +3 more
  • Rionero in Vulture, Italy
    IRCCS--CROB --CROB di Rionero in di Rionero in Vulture
2021-04-28
Apr 28, 2021
E
Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • Kiel, Germany
  • +2 more
2021-01-25
Jan 25, 2021
S
Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma - 2020
Completed
Has Results
  • Multiple Myeloma
  • Denver, Colorado
  • +12 more
2022-01-04
Jan 4, 2022
M
High Dose Carfilzomib for Newly Diagnosed Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
2021-11-18
Nov 18, 2021
M
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-11-01
Nov 1, 2021
N
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • New Haven, Connecticut
  • +4 more
2022-02-01
Feb 1, 2022